Tirzepatide commonly causes gastrointestinal side effects including nausea, diarrhea, vomiting, and constipation, which typically improve over time but may affect treatment decisions
These symptoms can overlap with and potentially worsen the gastrointestinal effects already associated with GLP-1 therapy, making it difficult to distinguish which agent is responsible for adverse effects
These are not easy standards to meet
This is why timing is so important
However, female subjects report higher rates of nausea at doses above 1mg compared to male subjects, likely due to sex differences in melanocortin-4 receptor density in the area postrema
Body aches in menopause, along with joint pain and swelling can be related to declining estrogen levels and sarcopenia (the natural decline of muscle tissue)